Prevention of risks associated with inappropriate use/unnecessary consumption of medicines.

Autor:	Cracowski JL; CRPV Grenoble, Université Grenoble Alpes, 38043 Grenoble, France., Muller S; GSK France, 92500 Rueil-Malmaison, France. Electronic address: sophie.m.muller@gsk.com., Anglade I; DGS, 75007 Paris, France., Bonnefond G; Syndicat des pharmaciens d'officine, 75009 Paris, France., Bouhanick B; Service d'hypertension artérielle et thérapeutique PCVM, UMR 1027, université de Toulouse 3, CHU de Rangueil, 31059 Toulouse, France., Bouquet S; Collège de médecine générale, 75017 Paris, France., Cabut S; Le Monde, 75013 Paris, France., Daynès P; Formation recherche, union francophone patients partenaire, 75012 Paris, France., Denis B; Formation recherche, union francophone patients partenaire, 75012 Paris, France., Durand D; LEEM, 75017 ParisFrance., Jonville-Béra AP; CRPV, CHRU de Tours, 37044 Tours, France., Lahouegue A; Pharmacovigilance et information médicale, AstraZeneca, 92400 Courbevoie, France., Léo M; Renaloo, 75013 Paris, France., Micallef J; CRPV, CEIP-addictovigilance, pharmacologie Aix-Marseille universités, 13005 Marseille, France., Molimard M; Inserm, BPH, U1219, pharmacoépidémiologie, université Bordeaux, 33000 Bordeaux, France., Penfornis C; Sanofi, 91385 Chilly-Mazarin, France., Querol-Ferrer V; LEEM, 75017 ParisFrance.
Jazyk:	angličtina
Zdroj:	Therapie [Therapie] 2022 Jan-Feb; Vol. 77 (1), pp. 79-88. Date of Electronic Publication: 2022 Jan 07.
DOI:	10.1016/j.therap.2022.01.003
Abstrakt:	In the code of public health, misuse is defined as intentional and inappropriate use of a medicine or product, which is not in accordance with the terms of the marketing authorisation or the registration as well as with good practice recommendations. Very often this involves an individual or the interaction of several individuals including the patient, his/her carers, prescriber(s) and/or dispensers. Misuse is common; it is the source of medicinal adverse effects for which a significant part is avoidable. Medicines initially prescribed or dispensed in the context of their marketing authorization (MA) can also be the subject of primary dependency and misappropriation. Companies which develop medicines nationally make declarations to the ANSM (French National Agency for the Safety of Medicines and Health Products) and implement measures to limit non-compliant use of their products. Recently, the coronavirus disease-2019 (COVID-19) pandemic has highlighted the influence and societal impact of drug misuse. The finding of the existence of systemic misuse, the impossibility of proposing simple solutions leads us to propose two main areas for improved information and the training of users and health professionals in medicines in the context of multi-faceted interventions: prevention of misuse on the one hand and its identification and treatment on the other hand. (Copyright © 2022. Published by Elsevier Masson SAS.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu